He was arrested in Grantham following proactive searches by officers in the town
A Lincoln mum says the right support can make the world of difference to deaf children, seeing first-hand the development of her seven-year-old son Marshall – but she is worried about consequences if that support is ever taken away.
As well as the great support given by the school, he also has access to a Teacher of the Deaf who came in to train staff and give them advice, as well as having one-on-one sessions with Marshall and after initial regular meetings she now sees him every few months. “Marshall socially struggled to make friends and couldn’t get involved in all the different conversations going on. The Teacher of the Deaf helped with this so that the staff could help him socialise with other children, he learnt to have one friend, to then two and more.”
Six in 10 said that deaf children will continue to underachieve at school without changes to the current system. The charity is urging the government to use this opportunity to develop a plan to provide effective, long-term specialist support. It wants to see investment in more Teachers of the Deaf, whose numbers it says have been slashed by 17% in a decade.Herminia added: “With deafness, a lot of speech you pick up informally from what is going on around you but he doesn’t have access to that as he has to focus on what being said to him.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
UK on brink of recession after economy shrinks againThe drop of 0.3% comes after similar turmoil earlier in the year, when in April gross domestic product fell by 0.3%, compared to a fall of 0.1% in March.
Read more »
Ukraine war: Stalemate in talks over disputed Zaporizhzhia power plant leaves an accident waiting to happenEurope's largest nuclear plant has been under Russian control since March and sits near the frontline of the war in territory President Putin has said has been annexed by Russia.
Read more »
Infantino receives CONMEBOL support FIFA re-electionFIFA president Gianni Infantino has received the backing of the South American football confederation, CONMEBOL, as he seeks re-election in March. The CONMEBOL member associations have unanimously united behind Infantino, who will be going for a third term as FIFA president next spring. This will be...
Read more »
Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate - The Journal of Prevention of Alzheimer's DiseaseBackground Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer’s disease (AD). Objectives The present report summarises the basis for selection of 16 mg/day as monotherapy as the optimal treatment regime and the design rationale of a confirmatory Phase 3 trial (LUCIDITY). Design The trial comprises a 12-month double-blind, placebo-controlled phase followed by a 12-month modified delayed-start open-label treatment phase. Setting 76 clinical research sites in North America and Europe. Participants 545 patients with probable AD or MCI-AD in the final version of the protocol. Intervention Participants were assigned randomly to receive hydromethylthione mesylate at doses of 16 mg/day, 8 mg/day or placebo at a 4:1:4 ratio during the double-blind phase. All participants in the open-label phase receive the 16 mg/day dose. Measurements Co-primary clinical outcomes are the 11-item Alzheimer’s Disease Assessment Scale (ADAS-cog11) and the 23-item Alzheimer’s Disease Cooperative Study — Activities of Daily Living (ADCS-ADL23). Secondary biomarker measures include whole-brain atrophy and temporal lobe 18F-fluorodeoxyglucose positron emission tomography. Results 446 participants are expected to complete the 12-month placebo-controlled phase in March 2022. Conclusions If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD. As low-dose oral hydromethylthionine mesylate is simple to use clinically, does not cause amyloid-related imaging abnormalities and has a benign safety profile, it would likely improve AD management.
Read more »
Wanted man back in prison after Grantham arrestHe was arrested in Grantham following proactive searches by officers in the town
Read more »